RGEN,ASRT Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

open in screener | publish chart | save to portfolio | create alert

Settings

RGEN [NASD]

Repligen Corporation

Healthcare | Medical Instruments & Supplies | USA

statements

Index	-	P/E	262.49	EPS (ttm)	0.58	Insider Own	0.80%	Shs Outstand	52.38M	Perf Week	1.23%
Market Cap	8.12B	Forward P/E	109.12	EPS next Y	1.40	Insider Trans	-32.70%	Shs Float	48.67M	Perf Month	18.73%
Income	30.90M	PEG	9.91	EPS next Q	0.28	Inst Own	88.80%	Short Float	3.51%	Perf Quarter	24.35%
Sales	302.50M	P/S	26.85	EPS this Y	19.10%	Inst Trans	-1.01%	Short Ratio	2.58	Perf Half Y	50.77%
Book/sh	21.00	P/B	7.27	EPS next Y	9.63%	ROA	2.20%	Target Price	159.43	Perf Year	63.02%
Cash/sh	10.54	P/C	14.49	EPS next 5Y	26.50%	ROE	2.90%	52W Range	72.32 - 159.97	Perf YTD	65.16%
Dividend	-	P/FCF	176.55	EPS past 5Y	12.10%	ROI	2.00%	52W High	-4.50%	Beta	1.15
Dividend %	-	Quick Ratio	13.90	Sales past 5Y	33.60%	Gross Margin	56.90%	52W Low	111.24%	ATR	5.25
Employees	761	Current Ratio	15.50	Sales Q/Q	23.80%	Oper. Margin	13.10%	RSI (14)	68.83	Volatility	3.41% 3.50%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	80.30%	Profit Margin	10.20%	Rel Volume	0.70	Prev Close	154.67
Shortable	Yes	LT Debt/Eq	0.22	Earnings	Jul 30 BMO	Payout	0.00%	Avg Volume	661.93K	Price	152.77
Recom	1.60	SMA20	9.52%	SMA50	18.91%	SMA200	44.34%	Volume	460,718	Change	-1.23%

Jun-30-20

Reiterated

H.C. Wainwright

Buy

$143 → $151

May-07-20

Reiterated

H.C. Wainwright

Buy

$100 → $143

Mar-23-20

Reiterated

H.C. Wainwright

Buy

$110 → $100

Nov-15-19

Initiated

Stifel

Buy

Nov-01-19

Upgrade

First Analysis Sec

Outperform → Strong Buy

$107 → $110

Oct-15-19

Initiated

SVB Leerink

Outperform

$100

Aug-28-19

Reiterated

First Analysis Sec

Outperform

$95 → $107

Aug-23-19

Resumed

Stephens

Overweight

Jul-22-19

Upgrade

H.C. Wainwright

Neutral → Buy

$110

Dec-17-18

Upgrade

CL King

Neutral → Buy

Nov-12-18

Downgrade

CL King

Buy → Neutral

Sep-26-18

Initiated

H.C. Wainwright

Neutral

$49

Dec-08-17

Initiated

Citigroup

Buy

$45

Dec-05-17

Initiated

JP Morgan

Overweight

$42

Nov-13-17

Initiated

CL King

Buy

Oct-02-17

Upgrade

First Analysis Sec

Equal-Weight → Overweight

$47

Jul-21-17

Initiated

William Blair

Outperform

Feb-13-17

Upgrade

Piper Jaffray

Neutral → Overweight

Feb-22-16

Initiated

Craig Hallum

Buy

Nov-06-15

Downgrade

Jefferies

Buy → Hold

Aug-03-20 02:33PM	Repligen Reports Record Quarter, Increases 2020 Guidance Motley Fool
01:10PM	Did Hedge Funds Drop The Ball On Repligen Corporation (RGEN) ? Insider Monkey
Jul-31-20 02:44PM	Dow Jones Slides 250 Points Despite Blowout Apple Earnings; Amazon, Facebook, Pinterest Surge On Earnings Investor's Business Daily
09:15AM	Repligen (RGEN) Hits Fresh High: Is There Still Room to Run? Zacks
Jul-30-20 10:28AM	Repligen Gaps Up On Earnings Investor's Business Daily Video +8.99%
09:15AM	Repligen (RGEN) Q2 Earnings and Revenues Top Estimates Zacks
07:30AM	Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance GlobeNewswire
Jul-23-20 03:27PM	Coronavirus Play Repligen Near Buy Zone With Earnings Due Investor's Business Daily
12:33PM	Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for Zacks
11:30AM	Has Repligen (RGEN) Outpaced Other Medical Stocks This Year? Zacks
Jul-22-20 11:40AM	EXEL vs. RGEN: Which Stock Should Value Investors Buy Now? Zacks
Jul-15-20 07:30AM	Repligen to Report Second Quarter 2020 Financial Results GlobeNewswire
Jul-08-20 01:23PM	Here's Why Repligen Rose 33.6% in the First Half of 2020 Motley Fool
Jul-03-20 11:40AM	LGND or RGEN: Which Is the Better Value Stock Right Now? Zacks
08:34AM	These 3 Stocks Are Potential Buyout Targets Motley Fool
Jun-29-20 07:30AM	Repligen Announces Agreement to Acquire Engineered Molding Technology GlobeNewswire
Jun-18-20 03:32PM	Repligen Corporation (RGEN): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Jun-17-20 11:40AM	LGND or RGEN: Which Is the Better Value Stock Right Now? Zacks
Jun-15-20 06:14PM	Edited Transcript of RGEN.OQ earnings conference call or presentation 6-May-20 12:30pm GMT Thomson Reuters StreetEvents
07:30AM	Repligen Appoints Carrie Eglinton Manner to Board of Directors GlobeNewswire
Jun-12-20 08:36AM	Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks Zacks
Jun-05-20 11:31AM	Repligen (RGEN) Down 0.4% Since Last Earnings Report: Can It Rebound? Zacks
May-28-20 11:40AM	QGEN vs. RGEN: Which Stock Is the Better Value Option? Zacks
11:34AM	Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen Zacks
May-27-20 09:15AM	Profit From 5 Stocks Likely to Beat on Earnings Zacks
May-13-20 12:20PM	Why Repligen (RGEN) Might be Well Poised for a Surge Zacks
May-08-20 10:23AM	Results: Repligen Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts Simply Wall St.
May-06-20 11:02PM	Repligen (RGEN) Q1 2020 Earnings Call Transcript Motley Fool +8.90%
03:40PM	Repligen Bucks Industry Trend, Increases Full-Year 2020 Guidance Motley Fool
11:48AM	Why Repligen's Stocks Is Trading Higher Today Benzinga
09:15AM	Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates Zacks
07:30AM	Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance GlobeNewswire
May-05-20 10:19AM	Will Clinical Trial Delays Derail Repligen's Growth? Motley Fool
Apr-29-20 12:33PM	Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-23-20 02:22PM	Why The 'Bad' Parts Of Its Base Aren't Hurting Repligen's Breakout Investor's Business Daily
Apr-22-20 04:22PM	Stocks Rebound As S&P 500 Still Faces A Key Test Investor's Business Daily +7.94%
07:30AM	Repligen to Report First Quarter 2020 Financial Results GlobeNewswire
Apr-21-20 04:31PM	Here's Why IBD Stock Of The Day Repligen Is 'Recession-Resistant' Investor's Business Daily
11:42AM	Repligen Sets Up Investor's Business Daily Video
Apr-11-20 10:15AM	How Should Investors React To Repligen Corporation's (NASDAQ:RGEN) CEO Pay? Simply Wall St.
Apr-05-20 09:03PM	Hedge Funds Are Selling Is Repligen Corporation (RGEN) Insider Monkey
Apr-01-20 06:00AM	Novavax and Regeneron- Speculating on Vaccines MoneyShow
Mar-21-20 11:30AM	Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? Zacks
Mar-19-20 04:17PM	IBD 50 Stocks To Watch: This Biotech Supplier Shows Spiking Relative Strength Investor's Business Daily -9.62%
Mar-12-20 10:58AM	Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet? Simply Wall St.
Feb-28-20 11:10AM	This Week On IBD Live (Feb. 28) Investor's Business Daily Video
Feb-27-20 07:30AM	Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors GlobeNewswire
Feb-21-20 10:32AM	Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat Zacks
Feb-20-20 11:50PM	Edited Transcript of RGEN earnings conference call or presentation 20-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -7.35%
08:45AM	Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates Zacks
07:30AM	Repligen Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
07:06AM	The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga
Feb-19-20 12:45PM	Repligen (RGEN) is an Incredible Growth Stock: 3 Reasons Why Zacks
Feb-13-20 12:31PM	Earnings Preview: Repligen (RGEN) Q4 Earnings Expected to Decline Zacks
Feb-06-20 07:30AM	Repligen to Report Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-04-20 06:41PM	Should Growth Investors Buy this Cancer Screening Biotech Stock? Zacks
Jan-30-20 11:10AM	Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks
Jan-24-20 10:15AM	Breakout Stocks & Technical Analysis Investor's Business Daily
Jan-17-20 08:45AM	ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-10-20 12:43PM	Investors Who Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago Are Now Up 289% Simply Wall St.
Jan-08-20 04:06PM	Stocks To Watch: Life Sciences Leader Repligen Tests New Buy With 84% Growth Investor's Business Daily
Jan-07-20 07:30AM	Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-19 02:04PM	A Look At The Fair Value Of Repligen Corporation (NASDAQ:RGEN) Simply Wall St.
Dec-09-19 11:30AM	Has Repligen (RGEN) Outpaced Other Medical Stocks This Year? Zacks
Dec-08-19 07:11PM	Hedge Funds Have Never Been This Bullish On Repligen Corporation (RGEN) Insider Monkey
Dec-06-19 12:45PM	3 Reasons Growth Investors Will Love Repligen (RGEN) Zacks
Dec-04-19 12:00PM	Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy Zacks
Dec-02-19 04:32PM	Hedge Funds Hit The Bullseye With This Stock Pick Insider Monkey
Nov-14-19 09:30AM	Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year? Zacks
Nov-06-19 04:08AM	Edited Transcript of RGEN earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
Nov-01-19 02:49PM	Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks +6.64%
Oct-31-19 09:15AM	Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates Zacks
07:30AM	Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance GlobeNewswire
Oct-30-19 11:49AM	Does Repligen Corporation's (NASDAQ:RGEN) CEO Pay Matter? Simply Wall St.
Oct-24-19 03:34PM	Hedge Funds Have Never Been More Bullish On Repligen Corporation (RGEN) Insider Monkey
10:32AM	Repligen (RGEN) Reports Next Week: What to Expect Zacks
Oct-23-19 10:29AM	Repligen to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-03-19 07:54PM	Edited Transcript of RGEN earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Sep-30-19 11:12AM	Does The Repligen Corporation (NASDAQ:RGEN) Share Price Fall With The Market? Simply Wall St.
Sep-24-19 05:38PM	Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes CNW Group
Sep-23-19 06:41AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Sep-14-19 06:31AM	3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-11-19 07:15PM	Repligen Corp (RGEN) CEO Anthony Hunt Sold $996,546 of Shares GuruFocus.com
Sep-09-19 02:19PM	Here's Why Repligen Has Dropped as Much as 13.1% Today Motley Fool -11.66%
Sep-06-19 06:00PM	S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600 PR Newswire
Aug-30-19 06:47AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Aug-28-19 07:11AM	3 Stocks to Buy and Hold for Decades Motley Fool
Aug-27-19 03:16PM	With EPS Growth And More, Repligen (NASDAQ:RGEN) Is Interesting Simply Wall St.
Aug-16-19 07:11AM	3 Growth Stocks for In-the-Know Investors Motley Fool
Aug-08-19 10:13AM	Should You Invest in the Invesco S&amp;P SmallCap Health Care ETF (PSCH)? Zacks
Aug-05-19 10:39AM	Repligen Grows Revenue 48% in Q2 Motley Fool
06:37AM	With A 3.0% Return On Equity, Is Repligen Corporation (NASDAQ:RGEN) A Quality Stock? Simply Wall St.
Aug-02-19 11:54AM	Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks -5.13%
10:53AM	Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
02:24AM	Repligen (RGEN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 12:02PM	Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks
12:00PM	Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
09:25AM	Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates Zacks
07:30AM	Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance GlobeNewswire
07:02AM	Powell Gives Space for Growth, Market Overreacts: 5 Picks Zacks

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RYAN THOMAS F JR	Director	Jul 31	Option Exercise	67.71	2,109	142,800	4,559	Aug 04 07:50 PM
RYAN THOMAS F JR	Director	Jul 31	Sale	151.90	3,095	470,129	1,464	Aug 04 07:50 PM
DAWES KAREN A	Director	Jun 18	Sale	115.20	18,705	2,154,851	100,734	Jun 22 04:42 PM
Hunt Anthony	Chief Executive Officer	May 21	Option Exercise	24.10	50,039	1,206,140	277,194	May 26 09:27 PM
Hunt Anthony	Chief Executive Officer	May 21	Sale	139.77	46,953	6,562,409	230,241	May 26 09:27 PM
DAWES KAREN A	Director	May 20	Sale	139.44	517	72,093	119,439	May 21 09:08 PM
BARTHELEMY NICOLAS	Director	May 18	Option Exercise	67.71	2,109	142,800	5,673	May 26 09:24 PM
BARTHELEMY NICOLAS	Director	May 18	Sale	142.53	3,009	428,873	2,664	May 26 09:24 PM
DAWES KAREN A	Director	May 18	Sale	137.78	1,600	220,448	119,956	May 19 08:46 PM
KURIYEL RALF	Senior VP, R&D	May 15	Sale	140.69	435	61,200	26,089	May 19 08:54 PM
Snodgres Jon	Chief Financial Officer	May 15	Sale	140.43	660	92,684	32,267	May 19 08:47 PM
KURIYEL RALF	Senior VP, R&D	May 13	Option Exercise	33.26	8,000	266,040	34,524	May 15 05:37 PM
Snodgres Jon	Chief Financial Officer	May 13	Option Exercise	30.75	12,194	374,956	48,321	May 15 05:41 PM
KURIYEL RALF	Senior VP, R&D	May 13	Sale	127.80	8,000	1,022,373	26,524	May 15 05:37 PM
Snodgres Jon	Chief Financial Officer	May 13	Sale	128.74	15,394	1,981,875	32,927	May 15 05:41 PM
BARTHELEMY NICOLAS	Director	Apr 22	Option Exercise	42.07	1,652	69,500	5,725	Apr 24 05:22 PM
BARTHELEMY NICOLAS	Director	Apr 22	Sale	109.99	2,688	295,653	3,037	Apr 24 05:22 PM
DAWES KAREN A	Director	Apr 21	Option Exercise	3.30	11,800	38,940	120,834	Apr 22 06:07 PM
DAWES KAREN A	Director	Apr 20	Option Exercise	3.30	8,200	27,060	121,234	Apr 22 06:07 PM
DAWES KAREN A	Director	Apr 20	Sale	104.57	12,200	1,275,717	109,034	Apr 22 06:07 PM
BARTHELEMY NICOLAS	Director	Apr 03	Option Exercise	42.07	1,652	69,500	6,761	Apr 06 07:34 PM
BARTHELEMY NICOLAS	Director	Apr 03	Sale	99.99	2,688	268,773	4,073	Apr 06 07:34 PM
Cox John	Director	Mar 24	Sale	96.72	1,858	179,706	923	Mar 26 07:31 PM
Cox John	Director	Mar 18	Option Exercise	24.37	26,736	651,603	29,517	Mar 20 04:25 PM
Cox John	Director	Mar 18	Sale	95.27	26,736	2,547,035	2,781	Mar 20 04:25 PM
RYAN THOMAS F JR	Director	Mar 16	Option Exercise	40.42	1,000	40,415	2,923	Mar 18 05:10 PM
RYAN THOMAS F JR	Director	Mar 16	Sale	91.48	1,000	91,480	1,923	Mar 18 05:10 PM
RYAN THOMAS F JR	Director	Mar 04	Option Exercise	41.70	4,796	200,015	6,719	Mar 05 05:53 PM
Cox John	Director	Mar 04	Option Exercise	12.91	10,000	129,100	12,781	Mar 05 05:52 PM
Hunt Anthony	Chief Executive Officer	Mar 04	Sale	90.13	12,300	1,108,599	230,241	Mar 05 05:50 PM
Snodgres Jon	Chief Financial Officer	Mar 04	Sale	90.39	1,045	94,458	36,127	Mar 05 05:53 PM
RYAN THOMAS F JR	Director	Mar 04	Sale	88.82	4,796	425,981	1,923	Mar 05 05:53 PM
Cox John	Director	Mar 04	Sale	93.39	10,000	933,900	2,781	Mar 05 05:52 PM
KURIYEL RALF	Senior VP, R&D	Mar 04	Sale	90.76	2,555	231,888	26,524	Mar 05 05:53 PM
KURIYEL RALF	Senior VP, R&D	Mar 03	Sale	88.35	450	39,758	29,079	Mar 05 05:53 PM
RYAN THOMAS F JR	Director	Mar 03	Sale	85.72	2,225	190,727	1,923	Mar 05 05:53 PM
Snodgres Jon	Chief Financial Officer	Mar 03	Sale	88.18	610	53,790	37,172	Mar 05 05:53 PM
Hunt Anthony	Chief Executive Officer	Mar 03	Sale	88.22	2,190	193,194	242,541	Mar 05 05:50 PM
Snodgres Jon	Chief Financial Officer	Feb 26	Sale	86.22	1,100	94,837	31,096	Feb 27 05:39 PM
Hunt Anthony	Chief Executive Officer	Feb 26	Sale	86.51	3,475	300,627	226,148	Feb 27 05:39 PM
KURIYEL RALF	Senior VP, R&D	Feb 26	Sale	86.60	195	16,887	26,313	Feb 27 05:38 PM
Hunt Anthony	Chief Executive Officer	Feb 25	Option Exercise	25.03	21,945	549,190	231,148	Feb 27 05:39 PM
Hunt Anthony	Chief Executive Officer	Feb 25	Sale	91.56	11,735	1,074,447	219,413	Feb 27 05:39 PM
Cox John	Director	Feb 24	Sale	92.81	4,455	413,455	2,781	Feb 26 04:27 PM
DAWES KAREN A	Director	Feb 21	Sale	98.70	4,000	394,793	113,034	Feb 24 05:51 PM
Snodgres Jon	Chief Financial Officer	Dec 05	Option Exercise	25.27	3,957	99,980	32,196	Dec 09 04:17 PM
Hunt Anthony	Chief Executive Officer	Sep 19	Option Exercise	16.55	20,000	331,000	223,013	Sep 23 06:02 PM
Hunt Anthony	Chief Executive Officer	Sep 19	Sale	82.89	3,600	298,390	219,413	Sep 23 06:02 PM
Hunt Anthony	Chief Executive Officer	Sep 09	Sale	82.40	12,094	996,521	203,013	Sep 11 04:58 PM

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

ASRT [NASD]

Assertio Holdings, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	3.40%	Shs Outstand	70.94M	Perf Week	-12.99%
Market Cap	98.65M	Forward P/E	5.22	EPS next Y	0.15	Insider Trans	-0.37%	Shs Float	61.33M	Perf Month	-4.44%
Income	-161.70M	PEG	-	EPS next Q	-0.03	Inst Own	64.80%	Short Float	2.52%	Perf Quarter	-1.84%
Sales	192.50M	P/S	0.51	EPS this Y	-634.30%	Inst Trans	19.95%	Short Ratio	1.03	Perf Half Y	-48.45%
Book/sh	1.18	P/B	0.66	EPS next Y	36.36%	ROA	-27.90%	Target Price	-	Perf Year	-72.11%
Cash/sh	-	P/C	-	EPS next 5Y	25.00%	ROE	-110.00%	52W Range	0.55 - 2.92	Perf YTD	-37.31%
Dividend	-	P/FCF	2.69	EPS past 5Y	-28.50%	ROI	-39.80%	52W High	-73.16%	Beta	2.18
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	-10.10%	Gross Margin	95.70%	52W Low	42.47%	ATR	0.08
Employees	125	Current Ratio	1.50	Sales Q/Q	-63.90%	Oper. Margin	-55.90%	RSI (14)	38.54	Volatility	10.01% 9.10%
Optionable	Yes	Debt/Eq	0.69	EPS Q/Q	360.70%	Profit Margin	-84.00%	Rel Volume	2.57	Prev Close	0.94
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	Payout	-	Avg Volume	1.50M	Price	0.78
Recom	2.00	SMA20	-14.41%	SMA50	-13.89%	SMA200	-16.46%	Volume	3,871,432	Change	-16.19%

Nov-30-18

Downgrade

Mizuho

Buy → Neutral

Aug-07-20 09:35AM	Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates Zacks -16.19%
07:23AM	Recap: Assertio Holdings Q2 Earnings Benzinga
06:02AM	Assertio Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-06-20 03:50PM	Preview: Assertio Therapeutics's Earnings Benzinga
Jul-31-20 12:30PM	Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks -6.67%
Jul-30-20 06:30AM	Maple Leaf Foods Reports Second Quarter 2020 Financial Results CNW Group
Jul-28-20 04:30PM	Maple Leaf Foods Closes Sale of Drummondville Poultry Plant to Giannone Poultry CNW Group +6.72%
Jul-27-20 05:00PM	Maple Leaf Foods Names Nadia Theodore Senior Vice President of Industry and Global Government Relations PR Newswire -5.36%
Jul-24-20 12:01PM	Maple Leaf Foods' (TSE:MFI) Shareholders Are Down 21% On Their Shares Simply Wall St.
Jul-20-20 06:02AM	Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020 GlobeNewswire
Jul-16-20 04:45PM	Maple Leaf Foods Announces Sale of Drummondville Poultry Plant to Giannone Poultry PR Newswire
04:45PM	Maple Leaf Foods Announces Sale of Drummondville Poultry Plant to Giannone Poultry CNW Group
07:00AM	Media Advisory - Maple Leaf Foods Inc. 2020 Second Quarter Financial Results Conference Call PR Newswire
07:00AM	Media Advisory - Maple Leaf Foods Inc. 2020 Second Quarter Financial Results Conference Call CNW Group
Jul-08-20 07:00AM	Maple Leaf Foods Releases 2019 Sustainability Report PR Newswire
Jun-30-20 11:50PM	Should You Avoid Assertio Holdings, Inc. (ASRT)? Insider Monkey
Jun-24-20 06:27PM	Maple Leaf Foods Inc. Announces Results of Vote For Election of Directors PR Newswire
May-22-20 07:24AM	STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Assertio Therapeutics, Inc. - ASRT PR Newswire -6.19%
May-21-20 06:30AM	Maple Leaf Foods Receives TSX Approval To Proceed With Normal Course Issuer Bid PR Newswire
May-20-20 06:20PM	Maple Leaf Foods Management Information Circular Now Available PR Newswire +13.01%
08:48AM	Assertio Completed Merger with Zyla Life Sciences PR Newswire
May-17-20 08:09AM	One Analyst's Earnings Estimates For Assertio Therapeutics, Inc. (NASDAQ:ASRT) Are Surging Higher Simply Wall St.
May-11-20 10:35AM	Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates Zacks +8.98%
08:17AM	Recap: Assertio Therapeutics Q1 Earnings Benzinga
08:00AM	Assertio Therapeutics Announces First-Quarter 2020 Results GlobeNewswire
May-08-20 10:41PM	SHAREHOLDER ALERT: Halper Sadeh LLP Investigates The Merger Of Assertio Therapeutics, Inc.; Investors Are Encouraged To Contact The Firm PR Newswire
10:10PM	ASSERTIO MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Assertio Therapeutics, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm ACCESSWIRE
07:02PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Assertio Therapeutics, Inc. PR Newswire
May-06-20 12:30PM	Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-20 12:00PM	All You Need to Know About Assertio (ASRT) Rating Upgrade to Buy Zacks
Apr-20-20 05:08PM	Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus GlobeNewswire
Apr-08-20 04:05PM	Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024 GlobeNewswire
Apr-02-20 06:24AM	Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Have A Particularly Volatile Share Price? Simply Wall St.
Mar-17-20 11:41AM	Wayne-based drug company enters into $17.5M merger deal American City Business Journals
10:15AM	Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies WLTW, TTPH, ASRT, MEET GlobeNewswire
Mar-16-20 06:45PM	Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products GlobeNewswire -6.25%
Mar-11-20 01:01AM	Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 GlobeNewswire +25.67%
Mar-09-20 05:55PM	Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates Zacks -6.14%
04:02PM	Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results GlobeNewswire
02:30AM	Assertio Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-20 04:14PM	The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues Benzinga
Mar-02-20 05:30PM	Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020 GlobeNewswire
Feb-26-20 12:30PM	Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-24-20 10:33AM	Assertio (ASRT) to Report Q4 Earnings: What's in Store? Zacks -10.69%
Feb-19-20 08:00AM	Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt GlobeNewswire +6.98%
Feb-17-20 06:00AM	Did Changing Sentiment Drive Assertio Therapeutics's (NASDAQ:ASRT) Share Price Down A Painful 93%? Simply Wall St.
Feb-14-20 08:23AM	The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering Benzinga
Feb-13-20 04:05PM	Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million GlobeNewswire
Feb-07-20 07:32AM	The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga +46.15%
Feb-06-20 04:01PM	Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million GlobeNewswire
Feb-04-20 05:45PM	Assertio (ASRT) Gains But Lags Market: What You Should Know Zacks
Jan-29-20 05:45PM	Assertio (ASRT) Dips More Than Broader Markets: What You Should Know Zacks
Jan-22-20 11:30AM	Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year? Zacks
Jan-15-20 05:45PM	Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-13-20 11:40AM	ASRT or PCRX: Which Is the Better Value Stock Right Now? Zacks
07:50AM	Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance GlobeNewswire
Jan-09-20 05:45PM	Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-08-20 10:18AM	Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks -6.09%
Jan-07-20 09:51AM	Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA Zacks +6.48%
09:17AM	Catalyst Gives Preliminary Firdapse Estimates & Other Updates Zacks
Dec-27-19 11:40AM	ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Dec-23-19 12:00PM	Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Dec-19-19 06:40AM	Need To Know: Assertio Therapeutics, Inc. (NASDAQ:ASRT) Insiders Have Been Buying Shares Simply Wall St.
Dec-13-19 03:07PM	Hedge Funds Are Crazy About Assertio Therapeutics, Inc. (ASRT) Insider Monkey
08:39AM	Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M Zacks
Dec-12-19 07:50AM	Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million GlobeNewswire +56.65%
Dec-10-19 11:40AM	ASRT vs. PCRX: Which Stock Should Value Investors Buy Now? Zacks +7.99%
Nov-26-19 02:29PM	Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-13-19 12:58PM	Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference GlobeNewswire +11.25%
Nov-07-19 11:26AM	PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales Zacks
Nov-06-19 07:45PM	Assertio (ASRT) Surpasses Q3 Earnings Estimates Zacks -12.08%
04:05PM	Assertio Therapeutics Announces Third-Quarter 2019 Results GlobeNewswire
Nov-04-19 06:05AM	How Much Did Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) CEO Pocket Last Year? Simply Wall St.
Oct-30-19 06:35PM	Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600 PR Newswire
10:34AM	Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-23-19 09:05AM	Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019 GlobeNewswire
Oct-22-19 07:51AM	The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug Benzinga
Oct-21-19 09:05AM	Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin GlobeNewswire -28.13%
Oct-13-19 04:33PM	The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-05-19 09:54AM	How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility? Simply Wall St.
Sep-30-19 12:35PM	Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors GlobeNewswire
Sep-26-19 08:00AM	Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-24-19 05:38PM	Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes CNW Group
Sep-20-19 09:40AM	ASRT vs. ZTS: Which Stock Is the Better Value Option? Zacks
Sep-09-19 09:50AM	Top Ranked Value Stocks to Buy for September 9th Zacks
Sep-05-19 11:05AM	If You Had Bought Assertio Therapeutics (NASDAQ:ASRT) Stock Three Years Ago, You'd Be Sitting On A 94% Loss, Today Simply Wall St.
Sep-04-19 09:30AM	ASRT vs. ZTS: Which Stock Should Value Investors Buy Now? Zacks
Aug-20-19 08:00AM	Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire -16.87%
07:59AM	Assertio Therapeutics Enters Oversold Territory Zacks
Aug-19-19 09:30AM	ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Aug-12-19 09:15PM	Assertio Therapeutics Inc (ASRT) Director, President and CEO Arthur J Higgins Bought $77,000 of ... GuruFocus.com
Aug-09-19 09:28AM	Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021 GlobeNewswire -45.91%
Aug-08-19 11:24PM	Assertio Therapeutics, Inc (ASRT) Q2 2019 Earnings Call Transcript Motley Fool +5.64%
Aug-07-19 07:35PM	Assertio (ASRT) Q2 Earnings Beat Estimates Zacks
04:02PM	Assertio Therapeutics Announces Strong Second-Quarter 2019 Results GlobeNewswire
Aug-06-19 03:22PM	Is Assertio Therapeutics (NASDAQ:ASRT) A Risky Investment? Simply Wall St.
Jul-31-19 10:36AM	Assertio (ASRT) Earnings Expected to Grow: Should You Buy? Zacks
Jul-26-19 09:30AM	ASRT or AMRX: Which Is the Better Value Stock Right Now? Zacks
Jul-17-19 04:05PM	Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019 GlobeNewswire -8.38%
Jul-01-19 08:39AM	La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza Zacks

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAWES KAREN A	Director	May 08	Sale	0.79	15,834	12,531	84,589	May 11 08:23 PM
Bukofzer Stan	SVP, Chf Scitfc & Tech Officer	Apr 02	Option Exercise	0.00	25,370	0	70,349	Apr 03 06:50 PM
Galeota James JR	Director	Mar 30	Option Exercise	0.00	12,492	0	12,492	Mar 31 07:32 PM
Mason Heather L	Director	Feb 18	Option Exercise	0.00	14,394	0	14,394	Feb 19 05:00 PM
Peisert Daniel A.	SVP and CFO	Feb 12	Option Exercise	0.00	27,588	0	112,753	Feb 12 06:41 PM
Bukofzer Stan	SVP, Chf Scitfc & Tech Officer	Feb 12	Option Exercise	0.00	27,588	0	54,524	Feb 12 06:40 PM
HIGGINS ARTHUR J	Director, President and CEO	Feb 12	Option Exercise	0.00	97,412	0	275,747	Feb 12 06:41 PM
HIGGINS ARTHUR J	Director, President and CEO	Feb 06	Option Exercise	0.00	62,399	0	199,925	Feb 06 05:49 PM
Peisert Daniel A.	SVP and CFO	Feb 06	Option Exercise	0.00	6,700	0	87,483	Feb 06 05:49 PM
HIGGINS ARTHUR J	Director, President and CEO	Dec 01	Option Exercise	0.00	34,860	0	147,739	Dec 02 05:20 PM
Peisert Daniel A.	SVP and CFO	Dec 01	Option Exercise	0.00	8,359	0	83,232	Dec 02 05:20 PM
HIGGINS ARTHUR J	Director, President and CEO	Nov 12	Buy	0.73	25,000	18,250	112,879	Nov 12 04:36 PM
Peisert Daniel A.	SVP and CFO	Nov 11	Buy	0.73	10,000	7,259	74,873	Nov 12 04:36 PM
STAPLE PETER D	Director	Nov 11	Buy	0.71	13,900	9,911	13,900	Nov 12 04:36 PM

open in screener | open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience